Recruiting
PHASE3
INTERVENTIONAL
NCT07064486
A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This trial is conducted in Indonesia. The aim of the trial is to evaluate the efficacy and safety of BGM0504 versus semaglutide as add-on to metformin in patients with type 2 diabetes
Interventions
Name:
BGM0504
Type:
DRUG
Description:
Administered SC
Name:
BGM0504
Type:
DRUG
Description:
Administered SC
Name:
Semaglutide
Type:
DRUG
Description:
Administered SC
Primary Outcomes
Measure:
Change From Baseline in Hemoglobin A1c (HbA1c)
TimeFrame:
Week 0 to Week 24
Description:
Change from baseline in HbA1c after 24 weeks of treatment.
Trial Information
NCT ID
NCT07064486
Status
Recruiting
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
BrightGene Bio-Medical Technology Co., Ltd.
Last Updated
December 15, 2025